BG104179A - Използване на фанхинон за лечението на болестта на алцхаймер - Google Patents

Използване на фанхинон за лечението на болестта на алцхаймер

Info

Publication number
BG104179A
BG104179A BG104179A BG10417900A BG104179A BG 104179 A BG104179 A BG 104179A BG 104179 A BG104179 A BG 104179A BG 10417900 A BG10417900 A BG 10417900A BG 104179 A BG104179 A BG 104179A
Authority
BG
Bulgaria
Prior art keywords
treatment
phanquinon
alzheimer
administration
disease
Prior art date
Application number
BG104179A
Other languages
English (en)
Other versions
BG64300B1 (bg
Inventor
Michel Xilinas
Panayotis GEROLYMATOS
Original Assignee
P.N. Gerolymatos S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by P.N. Gerolymatos S.A. filed Critical P.N. Gerolymatos S.A.
Publication of BG104179A publication Critical patent/BG104179A/bg
Publication of BG64300B1 publication Critical patent/BG64300B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретението се отнася до употреба на фанхинон за производството на фармацевтичен състав за профилактика или лечение на болестта на Алцхаймер, кактои до методи за нейното лечение и профилактика.
BG104179A 1997-08-21 2000-02-22 Използване на фанхинон за лечение на болестта на алцхаймер BG64300B1 (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GR97100330 1997-08-21
GR97100507 1997-12-31
PCT/IB1998/001095 WO1999009981A1 (en) 1997-08-21 1998-07-17 Use of phanquinone for the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
BG104179A true BG104179A (bg) 2000-10-31
BG64300B1 BG64300B1 (bg) 2004-09-30

Family

ID=26316681

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104179A BG64300B1 (bg) 1997-08-21 2000-02-22 Използване на фанхинон за лечение на болестта на алцхаймер

Country Status (25)

Country Link
US (2) US6670369B1 (bg)
EP (1) EP1007040B1 (bg)
JP (1) JP2001513558A (bg)
CN (1) CN1145482C (bg)
AT (1) ATE217191T1 (bg)
AU (1) AU741782B2 (bg)
BG (1) BG64300B1 (bg)
BR (1) BR9814945A (bg)
CA (1) CA2301706C (bg)
CZ (1) CZ299739B6 (bg)
DE (1) DE69805305T2 (bg)
DK (1) DK1007040T3 (bg)
EA (1) EA002526B1 (bg)
ES (1) ES2177024T3 (bg)
HK (1) HK1029937A1 (bg)
HU (1) HUP0004331A3 (bg)
IL (1) IL134263A (bg)
IS (1) IS1910B (bg)
NO (1) NO317770B1 (bg)
NZ (1) NZ502565A (bg)
PL (1) PL191208B1 (bg)
PT (1) PT1007040E (bg)
SK (1) SK284708B6 (bg)
TR (1) TR200000455T2 (bg)
WO (1) WO1999009981A1 (bg)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045531B1 (en) 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
US5994323A (en) * 1997-12-31 1999-11-30 P.N. Gerolymatos S.A. Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof
US6323218B1 (en) * 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US6638711B1 (en) 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
ATE285235T1 (de) 1999-01-07 2005-01-15 Gerolymatos P N Sa Verwendung von phanquinon zur behandlung und vorbeugung von gedächtnisschwund
WO2001082911A2 (en) * 2000-04-28 2001-11-08 Gerolymatos P N Sa TREATMENT OF PATHOLOGICAL CONDITIONS INFLUENCED BY THE ACTION OF MATRIX METALLOPROTEINASES (MMPs) USING CLIOQUINOL
WO2001082912A2 (en) * 2000-04-28 2001-11-08 Gerolymatos P N Sa TREATMENT OF PATHOLOGICAL CONDITIONS INFLUENCED BY THE ACTION OF MATRIX METALLOPROTEINASES (MMPs) USING PHANQUINONE
AU2000276021B2 (en) 2000-08-18 2006-04-06 The General Hospital Corporation Method for the identification of agents that inhibit or promote cataracts and uses thereof
FR2818551B1 (fr) * 2000-12-22 2007-06-01 Claude Marc Pierre Hannoun Utilisation de chelateurs pour le traitement des maladies a prions
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
ATE446685T1 (de) * 2003-03-11 2009-11-15 Kaneka Corp Öl-in-wasser-emulsion, die coenzym q10 enthält, und verfahren zu ihrer herstellung
US20080207673A1 (en) * 2005-05-04 2008-08-28 Michel Xilinas Method for Treating Cancer, Coronary, Inflammatory and Macular Disease, Combining the Modulation of Zinc-and/or Copper Dependent Proteins
WO2015165966A1 (en) * 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617417A1 (de) * 1966-12-08 1971-03-25 Ciba Geigy Pharmazeutisches Praeparat
DE1804736A1 (de) * 1967-11-02 1969-06-26 Ciba Geigy Pharmazeutisches Praeparat
IL40311A (en) 1972-09-06 1973-04-30 Pharmaplantex Ltd Pharmaceutical preparation for the treatment of gastro-intestinal troubles containing phanquone and furazolidone
GB1472257A (en) * 1973-09-10 1977-05-04 Christiaens Sa A Derivative of 4-hydroxy-5-azacoumarin
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4981844A (en) * 1988-10-04 1991-01-01 University Of Cincinnati Method to improve immune response and resistance to infection following surgery by diet composition
US5091391A (en) * 1990-08-16 1992-02-25 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of resisting neurodegenerative disorders
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
CA2078019C (en) * 1991-09-13 2002-08-27 Siegbert Heinrich Bissbort Substance or composition and uses thereof
JP3277211B2 (ja) 1991-11-12 2002-04-22 プラナ・バイオテクノロジー・リミテッド アルツハイマー病の試験方法と治療方法
GB9126874D0 (en) * 1991-12-18 1992-02-19 Wellcome Found Medicaments
WO1995031199A1 (en) * 1994-05-11 1995-11-23 P.N. Gerolymatos S.A. Use of clioquinol for treating helicobacter, including h. pylori, infections and related diseases
WO1997046526A1 (en) * 1996-06-07 1997-12-11 Eisai Co., Ltd. Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production
EP0959888B1 (en) 1996-08-13 2001-09-05 P.N. Gerolymatos S.A. Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
CA2284170C (en) 1997-03-11 2008-12-02 The General Hospital Corporation Identification of agents for use in the treatment of alzheimer's disease
US5980882A (en) * 1997-04-16 1999-11-09 Medeva Pharmaceuticals Manufacturing Drug-resin complexes stabilized by chelating agents
US5980914A (en) 1997-08-22 1999-11-09 P.N. Gerolymatos S.A. Clioquinol for the treatment of Parkinson's disease
US5994323A (en) 1997-12-31 1999-11-30 P.N. Gerolymatos S.A. Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof
ATE285235T1 (de) * 1999-01-07 2005-01-15 Gerolymatos P N Sa Verwendung von phanquinon zur behandlung und vorbeugung von gedächtnisschwund
WO2001082911A2 (en) 2000-04-28 2001-11-08 Gerolymatos P N Sa TREATMENT OF PATHOLOGICAL CONDITIONS INFLUENCED BY THE ACTION OF MATRIX METALLOPROTEINASES (MMPs) USING CLIOQUINOL
WO2001082912A2 (en) 2000-04-28 2001-11-08 Gerolymatos P N Sa TREATMENT OF PATHOLOGICAL CONDITIONS INFLUENCED BY THE ACTION OF MATRIX METALLOPROTEINASES (MMPs) USING PHANQUINONE

Also Published As

Publication number Publication date
HUP0004331A2 (hu) 2001-05-28
DK1007040T3 (da) 2002-08-26
PT1007040E (pt) 2002-10-31
IS1910B (is) 2003-12-31
US6670369B1 (en) 2003-12-30
IL134263A0 (en) 2001-04-30
HUP0004331A3 (en) 2001-09-28
AU741782B2 (en) 2001-12-06
DE69805305T2 (de) 2002-12-05
EA200000242A1 (ru) 2000-08-28
NO20000771D0 (no) 2000-02-16
PL191208B1 (pl) 2006-03-31
CN1267218A (zh) 2000-09-20
SK2062000A3 (en) 2000-08-14
NO317770B1 (no) 2004-12-13
US20050003018A1 (en) 2005-01-06
SK284708B6 (sk) 2005-09-08
NO20000771L (no) 2000-04-25
CZ299739B6 (cs) 2008-11-05
JP2001513558A (ja) 2001-09-04
AU8124198A (en) 1999-03-16
ATE217191T1 (de) 2002-05-15
TR200000455T2 (tr) 2000-09-21
WO1999009981A1 (en) 1999-03-04
NZ502565A (en) 2002-03-01
BR9814945A (pt) 2000-09-05
CN1145482C (zh) 2004-04-14
US7629354B2 (en) 2009-12-08
IL134263A (en) 2006-04-10
CZ2000611A3 (cs) 2000-08-16
CA2301706A1 (en) 1999-03-04
EA002526B1 (ru) 2002-06-27
BG64300B1 (bg) 2004-09-30
HK1029937A1 (en) 2001-04-20
EP1007040A1 (en) 2000-06-14
CA2301706C (en) 2005-10-04
IS5366A (is) 2000-01-28
ES2177024T3 (es) 2002-12-01
EP1007040B1 (en) 2002-05-08
PL338673A1 (en) 2000-11-20
DE69805305D1 (de) 2002-06-13

Similar Documents

Publication Publication Date Title
BG103740A (bg) Фитостеролен състав за предпазване от болестта наалцхаймер
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
AU3632497A (en) Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
MY137348A (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
BG106095A (bg) Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
GB0129260D0 (en) Pharmaceutical compositions and their uses
MX9602683A (es) Compuestos de 6-dimetilaminometil-1-fenil-ciclohexano como substancias farmaceuticamente activas.
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
BG104179A (bg) Използване на фанхинон за лечението на болестта на алцхаймер
BG105197A (bg) Полиморфна форма на лекарствено средство
EA199700151A1 (ru) Композиция для чрескожного введения
BG105275A (bg) Производни на tan-1057
BG102667A (bg) Състав, съдържащ диосгенин
PH31643A (en) 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease.
BG102707A (bg) Нови триазолопурини, метод за тяхното получаване и тяхното приложение като лекарствени средства
AU6415994A (en) Substituted caprolactams and derivatives thereof useful for treatment of hiv disease
BG106151A (bg) Фармацевтичен комплекс
ZA944281B (en) Use of efaroxan and its derivatives for the preparation of a medicinal product intented for the treatment of parkinson's disease
AU5768298A (en) Use of benzoylalkyl-1,2,3,6-tetrahydropyridins
MXPA05003633A (es) 2"-oxo-voruscharina y derivados de la misma.
UA23119A (uk) Психотропhий засіб